智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司收到国家药品监督管理局的通知,批准公司自主研发的1类创新药海曲泊帕乙醇胺片新增适应症。批准的适应症:本品联合免疫抑制治疗适用于15岁及以上初治重型再生障碍性贫血(SAA)患者。
海曲泊帕乙醇胺片于2021年获批上市两个适应症:1.本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者。2.本品适用于对免疫抑制治疗(IST)疗效不佳的重型再生障碍性贫血(SAA)成人患者。
智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司收到国家药品监督管理局的通知,批准公司自主研发的1类创新药海曲泊帕乙醇胺片新增适应症。批准的适应症:本品联合免疫抑制治疗适用于15岁及以上初治重型再生障碍性贫血(SAA)患者。
海曲泊帕乙醇胺片于2021年获批上市两个适应症:1.本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者。2.本品适用于对免疫抑制治疗(IST)疗效不佳的重型再生障碍性贫血(SAA)成人患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.